Effects of long-term growth hormone releasing hormone 1-29 in significantly short children.
Grunt. J A JA; Schwartz. I D ID; Buchanan. C C; Howard. C P CP
Key Findings
- Sermorelin was dosed at 30 µg per kg of body weight each day.
- Patients who grew at least 2 cm per year continued treatment; those who didn’t were stopped.
- Five out of seven children showed improved growth over a 24‑month period.
Practical Outcomes
- For adult biohackers, the study offers limited direct guidance because it focuses on children with a specific growth condition. It does suggest that daily sermorelin can boost growth when baseline GH is normal, but the small sample size and pediatric context mean you should be cautious about extrapolating to longevity or performance goals.
Summary
A tiny study gave a growth‑hormone‑releasing peptide (sermorelin) to seven kids who were unusually short but had normal growth‑hormone levels. Five of them kept taking it for two years and grew better, while two stopped after a year because they didn’t see enough growth.
Abstract
Seven children with significant idiopathic short stature (SISS) whose heights were significantly below the third percentile (SD score for height -2.5 to -3.5) and who had normal levels of growth hormone (GH) were treated with growth hormone releasing hormone (GH-RH) in a dose of 30 micrograms/kg/day. Therapy was discontinued if patients failed to increase their rates of growth by more than 2.0 cm/year over their pre-therapy growth rate. Treatment was discontinued in two of the patients after 12 months but was continued in the other five for 24 months. These data demonstrate that some patients with SISS grow well during the first 2 years of treatment with GH-RH.
Study Information
pubmed
1995
1995-06-01T00:00:00.000Z
10.1111/j.1651-2227.1995.tb13715.x
4
11